{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:15:33Z","timestamp":1790928933402,"version":"4.1.0"},"reference-count":129,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2010,6,28]],"date-time":"2010-06-28T00:00:00Z","timestamp":1277683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2011,9]]},"abstract":"<jats:p>Objective: To review the pharmacology, pharmacokinetics, in vitro and in vivo efficacy, and safety profile of vinflunine in the treatment of various solid tumors.<\/jats:p>\n                  <jats:p>Data sources: A literature search was conducted using keywords included vinflunine, vinca alkaloid, Javlor, and solid tumor in PubMed\/MEDLINE (1950\u2014January 2009) and International Pharmaceutical Abstracts (1950\u2014January 2009). Study selection and data extraction: Published studies, posters, and meeting abstracts evaluating the in vitro and in vivo efficacy of vinflunine were reviewed.<\/jats:p>\n                  <jats:p>Data synthesis: Vinflunine is the newest member of the vinca alkaloid family. It has the weakest affinity to tubulins, but is shown to have unique receptor-independent antiangiogenesis, and antimetastasis properties. After administration, it is distributed extensively into tissues, metabolized via the CYP3A4 system, and eventually excreted in urine and feces. Phase II\/III trials reported activities of vinflunine in advanced stage nonsmall-cell lung cancer, metastatic breast cancer, metastatic renal cell carcinoma, transitional cell carcinomas of the urothelium, small-cell lung cancer, and malignant pleural mesothelioma as monotherapy and in combination with other chemotherapy agents. More ongoing trials are evaluating its use in other solid tumors and in combination regimens. The most common adverse events in these trials were hematological (anemia and neutropenia), constipation, fatigue, abdominal pain, and myalgia.<\/jats:p>\n                  <jats:p>Conclusions: Vinflunine is a new vinca alkaloid for the treatment of advanced staged solid tumors. Available data showed promising activities in various malignancies. Further studies are needed to further define vinflunine\u2019s role in oncology.<\/jats:p>","DOI":"10.1177\/1078155210373525","type":"journal-article","created":{"date-parts":[[2010,6,29]],"date-time":"2010-06-29T00:06:59Z","timestamp":1277770019000},"page":"209-224","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":15,"title":["Vinflunine: review of a new\n                    <i>vinca<\/i>\n                    alkaloid and its potential role in oncology"],"prefix":"10.1177","volume":"17","author":[{"given":"John S","family":"Ng","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Wolfson Children's Hospital, Jacksonville, FL, USA; College of Pharmacy, University of Florida, Jacksonville, FL, USA,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2010,6,28]]},"reference":[{"key":"atypb1","unstructured":"Rowinsky EK and Donehower RC Antimicrotubule agents. In: Chabner BA, Longo DL (eds) Cancer chemotherapy and biotherapy. NY: Lippincott-Raven Publishers, 1996, p.263-296."},{"key":"atypb2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-3040"},{"key":"atypb3","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2008.01.005"},{"key":"atypb4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-2249"},{"key":"atypb5","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(59)90123-6"},{"key":"atypb6","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2008.01.009"},{"key":"atypb7","first-page":"173","volume":"24","author":"Svoboda GH","year":"1961","journal-title":"Lloyda"},{"key":"atypb8","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(96)90032-8"},{"key":"atypb9","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2008.01.004"},{"key":"atypb10","unstructured":"Rowinsky EK and Tolcher A. Antimicrotubule agents. In: DeVita Jr VT, Hellman S, Rosenberg SA (eds) Cancer principles & practice of oncology , 7th edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2005, p.390-416."},{"key":"atypb11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2008.07.025"},{"key":"atypb12","doi-asserted-by":"publisher","DOI":"10.1021\/ja00438a046"},{"key":"atypb13","doi-asserted-by":"publisher","DOI":"10.1021\/jo01336a006"},{"key":"atypb14","doi-asserted-by":"publisher","DOI":"10.1021\/ja971864w"},{"key":"atypb15","unstructured":"Jacquesy JC and Fahy J. Cancer: superacid generation of new antitumor agents. In: Torrence PF (ed.) Biomedical chemistry: applying chemical principles to the understanding and treatment of disease. New York, NY: Wiley-Interscience, 2000, p.227-246."},{"key":"atypb16","doi-asserted-by":"publisher","DOI":"10.2174\/1381612013397483"},{"key":"atypb17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-2219"},{"issue":"8","key":"atypb18","first-page":"2212","volume":"51","author":"Jordan MA","year":"1991","journal-title":"Cancer Res"},{"key":"atypb19","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1317"},{"key":"atypb20","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(97)00505-4"},{"issue":"3","key":"atypb21","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0026-895X(24)05641-4","volume":"66","author":"Pourroy B.","year":"2004","journal-title":"Mol Pharmacol"},{"key":"atypb22","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-005-0147-8"},{"key":"atypb23","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2008.01.007"},{"key":"atypb24","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600025"},{"key":"atypb25","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(01)00183-4"},{"key":"atypb26","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199907000-00005"},{"key":"atypb27","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(98)00416-X"},{"key":"atypb28","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-2624"},{"key":"atypb29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.06.019"},{"key":"atypb30","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-08-0156"},{"key":"atypb31","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1587"},{"key":"atypb32","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-005-3902-0"},{"key":"atypb33","first-page":"221","volume":"22","author":"Vermoken JB","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"atypb34","doi-asserted-by":"publisher","DOI":"10.1007\/BF03191120"},{"key":"atypb35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1745-7254.2007.00484.x"},{"key":"atypb36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.2005.00367.x"},{"key":"atypb37","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg174"},{"key":"atypb38","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.14.10.1259"},{"key":"atypb39","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.me.42.020191.001425"},{"key":"atypb40","doi-asserted-by":"publisher","DOI":"10.1007\/BF00744668"},{"key":"atypb41","doi-asserted-by":"publisher","DOI":"10.1007\/BF00873957"},{"key":"atypb42","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006022811895"},{"key":"atypb43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.9.3004"},{"key":"atypb44","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.39.1.361"},{"key":"atypb45","doi-asserted-by":"publisher","DOI":"10.1101\/gr.GR-1649R"},{"key":"atypb46","first-page":"385","volume":"62","author":"Gottesman MM","year":"1993","journal-title":"Annu Rev Med"},{"key":"atypb47","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-06-0277"},{"key":"atypb48","doi-asserted-by":"crossref","unstructured":"Carre M. and Braguer D. Microtubule damaging agents and apoptosis. In: Fojo T (ed.) Role of microtubules in cell biology, neurobiology, and oncology. Totowa, NJ: Humana Press, 2008, p.479-518.","DOI":"10.1007\/978-1-59745-336-3_18"},{"key":"atypb49","doi-asserted-by":"publisher","DOI":"10.1007\/s002800100275"},{"key":"atypb50","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603106"},{"key":"atypb51","doi-asserted-by":"publisher","DOI":"10.1016\/S1078-1439(02)00184-9"},{"key":"atypb52","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603118"},{"issue":"6","key":"atypb53","first-page":"4363","volume":"25","author":"Erjala K.","year":"2005","journal-title":"Anticancer Res"},{"key":"atypb54","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(97)90004-6"},{"key":"atypb55","first-page":"1087","volume":"4","author":"Bunn Jr A.","year":"1998","journal-title":"Clin Cancer Res"},{"key":"atypb56","doi-asserted-by":"publisher","DOI":"10.1007\/s002800051021"},{"issue":"6","key":"atypb57","first-page":"4815","volume":"23","author":"Shnyder SD","year":"2003","journal-title":"Anticancer Res"},{"key":"atypb58","first-page":"41","volume":"23","author":"Edelstein MP","year":"1996","journal-title":"Semin Oncol"},{"key":"atypb59","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-5002(01)00265-3"},{"key":"atypb60","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-8-65"},{"key":"atypb61","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-007-0587-4"},{"key":"atypb62","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-002-0430-x"},{"key":"atypb63","doi-asserted-by":"publisher","DOI":"10.1080\/02841860310023110"},{"key":"atypb64","doi-asserted-by":"publisher","DOI":"10.2307\/3572025"},{"key":"atypb65","doi-asserted-by":"publisher","DOI":"10.1126\/science.140.3566.490"},{"key":"atypb66","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-006-6437-0"},{"issue":"18","key":"atypb67","first-page":"S23","volume":"20","author":"Bunn PA","year":"2002","journal-title":"J Clin Oncol"},{"issue":"5","key":"atypb68","first-page":"27","volume":"18","author":"Natale RB","year":"2004","journal-title":"Oncology"},{"key":"atypb69","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2004.10.014"},{"key":"atypb70","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.13.3210"},{"key":"atypb71","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011954"},{"key":"atypb72","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010801)92:3<595::AID-CNCR1359>3.0.CO;2-D"},{"key":"atypb73","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008336931378"},{"key":"atypb74","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.25.18_suppl.7511"},{"key":"atypb75","volume-title":"Vinflunine and cetuximab as second-line therapy in treating patients with stage IIIB or stage IV non-small cell lung cancer","author":"US National Institutes of Health.","year":"2010"},{"issue":"16","key":"atypb76","first-page":"S688","volume":"23","author":"Tourani K.","year":"2005","journal-title":"J Clin Oncol"},{"key":"atypb77","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.22.14_suppl.7110"},{"key":"atypb78","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.3841"},{"key":"atypb79","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-006-0030-8"},{"key":"atypb80","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.25.18_suppl.18091"},{"key":"atypb81","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf101"},{"key":"atypb82","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.9-6-617"},{"key":"atypb83","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.4.1395"},{"key":"atypb84","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2003.37267"},{"key":"atypb85","doi-asserted-by":"publisher","DOI":"10.1159\/000069315"},{"key":"atypb86","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.10.047"},{"key":"atypb87","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.10.024"},{"key":"atypb88","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.2.485"},{"key":"atypb89","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2003.11.007"},{"key":"atypb90","doi-asserted-by":"publisher","DOI":"10.1023\/A:1010679127390"},{"key":"atypb91","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603347"},{"key":"atypb92","doi-asserted-by":"publisher","DOI":"10.1126\/science.3798106"},{"key":"atypb93","doi-asserted-by":"publisher","DOI":"10.1126\/science.2470152"},{"key":"atypb94","first-page":"165","volume":"1198","author":"Hynes NE","year":"1994","journal-title":"Biochim Biophys Acta"},{"key":"atypb95","doi-asserted-by":"publisher","DOI":"10.1016\/0378-1119(94)00866-Q"},{"key":"atypb96","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.3.719"},{"key":"atypb97","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.25.18_suppl.1058"},{"key":"atypb98","volume-title":"In: 31st annual San Antonio Breast Cancer symposium","author":"Yardley D."},{"key":"atypb99","volume-title":"Trial of vinflunine plus capecitabine in advanced breast cancer","author":"US National Institutes of Health.","year":"2010"},{"key":"atypb100","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.12.2419"},{"key":"atypb101","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602209"},{"key":"atypb102","first-page":"NS","author":"Bladder Cancer Guidelines.","year":"2007","journal-title":"J Natl Compr Canc Netw"},{"key":"atypb103","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)48996-8"},{"key":"atypb104","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3068"},{"issue":"18","key":"atypb105","first-page":"S653","volume":"25","author":"Vaughn DJ","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"atypb106","first-page":"309","author":"Petrylak DP","year":"2007","journal-title":"Eur J Cancer"},{"key":"atypb107","volume-title":"Phase III Trial of vinflunine plus best supportive care versus best supportive care in patients with transitional cell carcinoma (TCC) of the urothelial tract","author":"US National Institutes of Health.","year":"2010"},{"key":"atypb108","volume-title":"First-line treatment of advanced bladder cancer randomized versus. gemcitabine \u00b1 vinflunine in patients ineligible to receive cisplatin-based therapy","author":"US National Institutes of Health.","year":"2010"},{"key":"atypb109","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.5641"},{"key":"atypb110","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19831201)52:11<1981::AID-CNCR2820521102>3.0.CO;2-P"},{"key":"atypb111","doi-asserted-by":"publisher","DOI":"10.1007\/BF00175403"},{"key":"atypb112","doi-asserted-by":"publisher","DOI":"10.1007\/BF00685720"},{"key":"atypb113","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.23.3912"},{"key":"atypb114","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.136"},{"key":"atypb115","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi094"},{"issue":"22","key":"atypb116","first-page":"S622","author":"Van Meerbeeck JP","year":"2004","journal-title":"J Clin Oncol"},{"key":"atypb117","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8619(18)30259-7"},{"key":"atypb118","doi-asserted-by":"publisher","DOI":"10.1007\/PL00007853"},{"key":"atypb119","doi-asserted-by":"publisher","DOI":"10.1016\/1040-8428(93)90006-P"},{"key":"atypb120","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0169(1998)39:2<107::AID-CM2>3.0.CO;2-3"},{"key":"atypb121","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpc.2006.05.023"},{"key":"atypb122","doi-asserted-by":"publisher","DOI":"10.1021\/bi001038r"},{"key":"atypb123","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0026-895X(24)13258-0","volume":"53","author":"Lobert S.","year":"1998","journal-title":"Mol Pharmacol"},{"key":"atypb124","volume-title":"Summary of product characteristics (Javlor)","author":"European Medicines Agency.","year":"2010"},{"key":"atypb125","volume-title":"Effect of ketoconazole on the pharmacokinetics of vinflunine","author":"US National Institutes of Health.","year":"2010"},{"key":"atypb126","volume-title":"A study of vinflunine in patients with gastric cancer","author":"US National Institutes of Health.","year":"2010"},{"key":"atypb127","volume-title":"Vinflunine in hormone refractory prostate cancer (HRPC)","author":"US National Institutes of Health.","year":"2010"},{"key":"atypb128","volume-title":"A study of the alternative administration of ixabepilone and vinflunine","author":"US National Institutes of Health.","year":"2009"},{"key":"atypb129","volume-title":"Vinflunine and erlotinib or pemetrexed in treating patients with unresectable or metastatic solid tumors","author":"US National Institutes of Health.","year":"2010"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155210373525","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155210373525","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:13:56Z","timestamp":1777688036000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155210373525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,28]]},"references-count":129,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["10.1177\/1078155210373525"],"URL":"https:\/\/doi.org\/10.1177\/1078155210373525","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,28]]}}}